THE NASH CHALLENGE
 
Non-alcoholic steatohepatitis (NASH) is a form of fatty liver disease (steatosis) that occurs in persons who drink little or no alcohol. Untreated it can progress to fibrosis, cirrhosis and hepatocellular cancer.  10% of children and young people diagnosed with NAFLD progress to advanced liver fibrosis and are at risk of developing advanced stages of liver disease. The only way to identify people with NASH is by performing an invasive liver biopsy. There is an urgent need for technology for early detection and assessment of the severity of NAFLD. Stemnovate brings to market liver platform that can help the scientific community, clinicians and pharma develop better diagnosis and novel treatments for NASH.
stemnovate
Platform Features
  1. World’s first commercial biobank for renewable liver cells from induced pluripotent stem cells.
  2. Multicellular modelling  (Stellates, Kupffer cells, endothelial cells)to simulate liver microarchitecture
  3. Robust data platform powered with transcriptomics and Genotyping for finding new biomarkers
  4. Advanced system ‘on a chip’ for microphysiological modelling
  5. Patient samples for studying genetic predisposition and variable responses
stemnovate
BIOINFORMATICS AND DEEP LEARNING

Stemnovate in vitro testing platform simulates the liver response to evaluate predictable and unpredictable hepatotoxins over the breadth of the genetically diverse human population. The processes are highly data-driven with high-resolution images, genomic profiles, biological information, molecular and metabolite profiles. The machine learning can correlate, assimilate and connect the data more rapidly to help discover patterns. Our approach for deep learning will allow data exploration to identify key features and design of the cognitive network that can automate the prediction of toxicity and will be a game-changing technology for precision drug discovery.

  1. Stemnovate is capable of designing and manufacturing a bespoke fluidic component to enhance repeatability of complex cell culture
  2. As a company, we are able to quickly design, validate and manufacture prototypes and complex designs
  3. Once a methodology is optimised the process can be set for reproducibility and automation
  4. We support projects to achieve a higher standard of accuracy, evaluating biocompatibility and tolerance.
Products

Induced Pluripotent stem cell lines

Human & Multispecies Primary cells

Cell culture & analysis package

Services

Cell Reprogramming

Cell Differentiation

Application Development

Data

Pharmacogenomic Data 

Single Nucleotide Polymorphism

Transcriptomics

Pharmacokinetic/Pharmacodynamic Data

Device

Microphysiological systems

Microfluidic design, prototyping and manufacturing

Biosensing and Automation

Our clients say

You are doing some amazing and important work at Stemnovate, we are happy to be associated with your project.

Volunteer
Volunteer for blood donation for liver research

Thank you for your presentations, they were really great and stimulating. I am very happy we met and that we could get the cells in culture!

Academic Institution
University of Bern

CASE STUDIES & Partnership

Hepatitis C: Could this research help us tackle viruses?

Prof Cliona O’Farrelly is on a mission to find out why some people…

13.09.2019
Stemnovate partners with ANB sensors for the biosensing of cell culture systems

Stemnovate and partner ANB sensors are working together as part of Liver-on-a-chip project to develop biosensors that have potential to provide microenvironment information of the cell culture systems, especially the pH measurements. The advantage is for improving the reproducibility of the cell systems and defining optimum culture conditions.  ANB Sensors are also based in Cambridge […]

28.10.2019